Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra fast-acting insulin analogue - Adocia

X
Drug Profile

Ultra fast-acting insulin analogue - Adocia

Alternative Names: BC 106 Insulin Lispro; BC 222 Insulin Lispro; BC Lispro; BioChaperone Lispro; BioChaperone® insulin analogue; BioChaperone® insulin lispro; BioChaperone® Lispro U100; BioChaperone® Lispro U200; BioChaperone® Ultra Fast Lispro; THDB-0206

Latest Information Update: 26 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adocia
  • Developer Adocia; Tonghua Dongbao Pharmaceutical
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II/III Type 1 diabetes mellitus

Most Recent Events

  • 12 Dec 2024 Tonghua Dongbao Pharmaceutical expects to submit Marketing Authorization Application to the Chinese Centre for Drug Evaluation for Type 2 diabetes mellitus (SC), in 2025
  • 12 Dec 2024 Tonghua Dongbao Pharmaceutical completes enrolment in its phase III trial for Type 2 diabetes mellitus in China (SC)
  • 22 Sep 2023 Meitheal Pharmaceuticals enters into an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical to commercialize products in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top